Vasomedical Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc.

VASO 0.155

0.0%

Dec 3 10:42 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SG who wrote (912)	3/31/1998 10:50:00 PM
From: Fred Levine	Read Replies (1) of 1605

EECP has, from the first study, demonstrated improved clinical and physiological functioning. The patients initially selected were those that were resistant to other forms of intervention, and had a 3 year survival rate of 88%. That study, as far as I can recall, did not have a control group. I have all the research in my car and will review it tomorrow. I think that even if the morbidity rate were identical to other forms of intervention, the noninvasive character of the treatment and lower expense are benefits. I have a vital (as well as financial)interest in the answer to the morbidity question. good investing and health -- fred

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next